For decades, influenza has resisted our best efforts to protect those most vulnerable to it — older adults whose aging immune systems respond less vigorously to standard vaccines. Now, a large international trial published in The Lancet Infectious Diseases suggests that combining three separately proven vaccine technologies into a single formulation may offer meaningfully stronger protection for adults over fifty, marking a rare moment when incremental science converges into something greater than the sum of its parts.